Metabolic Signaling Research

Retatrutide — 10 mg

Name: Retatrutide — 10 mg
Brand: Vectrum Peptides
Price: 80.0 EUR
Availability: InStock

10 mg / vial

Retatrutide is an investigational peptide that activates GLP-1, GIP and glucagon receptors. These hormone systems affect hunger, digestion, insulin, blood sugar and energy use. Human trial results apply to the specific investigational drug, not this 10 mg laboratory vial.

Sale 20% off €100,00€80,00

Research only Secure checkout Document available

For in-vitro laboratory research only. Not for human or veterinary use.This information is provided for scientific and educational product context only. It does not describe or recommend human use, veterinary use, diagnosis, treatment, prevention, dosage, administration, or clinical application.

Weight Loss

Human studies found large average reductions in body weight. Most of the weight lost came from body fat, although results differed between people.

Less Hunger

It affects hunger and fullness signals. People may feel less hungry, become full sooner and find it easier to eat less.

Blood Sugar and Insulin

It helps the body release insulin when blood sugar rises. This can improve how the body handles sugar after eating.

Body Fat and Liver Fat

Research found reductions in stored body fat and fat inside the liver. The liver helps process and store energy.

Energy Use

It affects hormone signals involved in how the body uses food and stored energy.

Retatrutide remains investigational, and results differ between people.

Document available

Product document

Analytical documentation

Open the document and check that its product and batch details match your item.

Product: Retatrutide — 10 mg
Document type: Analytical document

This document applies only to the product and batch printed on it.

Full research details

Full research details for Retatrutide — 10 mg

Read the supporting laboratory, animal and human research. This section does not provide instructions for human or veterinary use, diagnosis, treatment, prevention, dosage or administration.

What this compound is

Retatrutide is an investigational peptide that can signal through the GLP-1, GIP and glucagon receptors. This product page identifies the 10 mg laboratory reference format. Research on the molecule ranges from receptor-structure work to animal models and phase 2 and phase 3 trials in people. Human trial data concern a controlled investigational drug product, not the identity or performance of this storefront material.

MaterialInvestigational triple-receptor peptide

Main research areaMetabolic hormone receptor research

Evidence availableMechanistic, animal and phase 2/3 human studies

Catalogue categoryMetabolic Signaling Research

How It Works

Normal target and function. After food, GLP-1 signalling can slow stomach emptying and reduce hunger signals, while GLP-1 and GIP help the pancreas release insulin when glucose is present. The glucagon receptor helps release stored fuel and maintain glucose supply. Retatrutide activates all three systems, so researchers measure the combined changes in blood glucose, appetite-related signals and body weight.

The three target receptors are part of the body's system for managing food-related signals, glucose and stored energy. Researchers study whether a single peptide can produce a useful, balanced pattern across all three. Laboratory work maps how the molecule contacts each receptor and which messages follow inside cells. Human trials have measured metabolic and body-weight outcomes, but retatrutide remains under investigation and no trial result should be read as a personal-use instruction.

GLP-1 signal

One part of the research examines a receptor involved in food-related and glucose signals.

GIP signal

A second receptor connects nutrient sensing with metabolic cell responses.

Glucagon signal

The third receptor is involved in glucose supply and energy regulation.

Trial context

Human studies are investigational and apply only to the exact drug product and protocol tested.

Laboratory and Animal Research

Structural and cell studies show how retatrutide contacts and activates each receptor. Animal models reported changes in glucose and energy-related endpoints that supported later trials. Those findings explain the research pathway but do not prove the performance of this 10 mg reference vial.

Measurements used in these studies

How retatrutide fits and activates each receptor
The messages produced inside receptor-bearing cells
Energy and glucose endpoints in preclinical models
HbA1c, body-weight and safety outcomes in phase 2 and phase 3 trials

Human Research

What human studies have reported

Phase 2 trials in obesity and type 2 diabetes and a published 2026 phase 3 diabetes trial found lower body-weight and blood-glucose measurements with an investigational retatrutide product. The studies do not turn retatrutide into an approved medicine or establish equivalence for this storefront material.

Effects researchers measured

Body-weight change was a major measured outcome in controlled trials.
HbA1c and related glucose measurements improved in the type 2 diabetes trials.
The 2026 phase 3 trial strengthens evidence for the exact investigational product studied, not for unverified products with the same compound name.

Adverse effects reported

Nausea, diarrhoea, vomiting and constipation were the most frequently reported events in the phase 2 obesity trial.
Gastrointestinal events were generally mild to moderate and tended to lessen over time in the phase 3 diabetes trial.
The phase 2 obesity trial observed a temporary, dose-related rise in heart rate.

Product boundary. The trials used controlled pharmaceutical formulations and monitored protocols. The catalogue amount “10 mg” is a product descriptor, not a dosing instruction or proof of trial-product equivalence.

Evidence type	What was studied	How much evidence	What this means
Laboratory research	Receptor structure and signalling	Mechanistic	The three receptor interactions have been examined in controlled laboratory systems.
Animal research	Metabolic response models	Preclinical	Animal findings helped shape clinical research but are not direct human evidence.
Human research	Controlled phase 2 and phase 3 trials	Meaningful investigational evidence	Trials reported changes in blood-glucose and body-weight measures. They do not establish an approved use or this listing's equivalence.

Limits of the Evidence

Retatrutide remains investigational and is not an approved medicine.
Human findings belong to the studied pharmaceutical formulation and monitored trial conditions.
Important questions about longer-term outcomes remain open.